Workshop on primary progressive multiple sclerosis: meeting summary.
Montalban
X
X
Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain. xmontal@ar.vhebron.es
Thompson
A J
AJ
D000328:Adult; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003952:Diagnostic Imaging; D005060:Europe / Q000453:epidemiology; D005260:Female; D020022:Genetic Predisposition to Disease; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009836:Oligodendroglia / Q000473:pathology; D010455:Peptides / Q000627:therapeutic use; D011446:Prospective Studies; D012189:Retrospective Studies; D019782:Riluzole / Q000627:therapeutic use
D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D019782:Riluzole; D000068556:Interferon beta-1a